Why Stopping Statins After 75 May Not Improve Health or Quality of Life
Statins lower cholesterol, and many older adults take one for years without ever having had a heart attack or stroke. For that group, the value of continuing can become less obvious. A team at the University Hospital Bordeaux studied the question directly, using patients from French general practices.
All participants were at least 75 years old. Each had been taking a statin for at least a year, and none had diagnosed vascular disease. They were using the drug for prevention rather than to treat an existing arterial condition. That distinction shapes what the study can and cannot say.
What the three-year comparison found
The investigators followed people who stayed on the statin and people who stopped it. After three years, 7.9 percent of those who continued had died, compared with 7.2 percent in the group that stopped. Serious cardiovascular events were also close: 4.4 percent under treatment versus 5.0 percent without it. In statistical terms, stopping was not inferior to continuing.
One result may be unexpected. The people who stopped did not feel better. Adverse events occurred at nearly the same rate in both groups, 73.1 percent versus 74.0 percent, and quality-of-life scores were similar after three years.
Why the researchers urge caution
The Bordeaux team acknowledged that the study came out smaller than planned. The original target was 2,430 participants, but only 1,180 were enrolled. Fewer deaths occurred than expected, which makes the estimates less precise.
The researchers warned against turning the result into a blanket rule, as the Berliner Morgenpost reported. Stopping can make sense when a patient wants to reduce the overall number of medications, when life expectancy is limited, when the pill burden is high, or when treatment goals change. Age alone is not a sufficient reason.
Who should not stop based on this study
The German Heart Foundation draws a clear boundary. People with coronary heart disease or another arteriosclerotic condition still benefit from statins after age 75, with protection against heart attack and stroke. Earlier studies, the foundation notes, have found that stopping in old age can be especially dangerous in that group.
The Bordeaux study does not apply to those patients because it included only people without such a diagnosis. The practical takeaway is not that everyone over 75 should stop, or keep going. It is that the decision should follow the original reason for the prescription and be made with a doctor.